AXNX Axonics Inc

Price (delayed)

$58.57

Market cap

$2.76B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.8

Enterprise value

$2.55B

Based in Irvine, Calif., Axonics has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for patients with bladder and bowel dysfunction, and through its acquisition of BulkamidĀ®, offers ...

Highlights
The company's debt has shrunk by 88% YoY and by 3.2% QoQ
AXNX's gross profit has surged by 81% year-on-year and by 11% since the previous quarter
AXNX's equity is up by 40% year-on-year but it is down by 3.9% since the previous quarter
AXNX's EPS is down by 10% year-on-year but it is up by 3.2% since the previous quarter
The net income has contracted by 28% YoY

Key stats

What are the main financial stats of AXNX
Market
Shares outstanding
47.07M
Market cap
$2.76B
Enterprise value
$2.55B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
5.93
Price to sales (P/S)
13.6
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
13.14
Earnings
Revenue
$194.34M
EBIT
-$73.74M
EBITDA
-$62.72M
Free cash flow
-$33.32M
Per share
EPS
-$1.8
Free cash flow per share
-$0.74
Book value per share
$9.87
Revenue per share
$4.31
TBVPS
$7.13
Balance sheet
Total assets
$525.57M
Total liabilities
$62.14M
Debt
$10.09M
Equity
$463.43M
Working capital
$281.91M
Liquidity
Debt to equity
0.02
Current ratio
12.05
Quick ratio
9.43
Net debt/EBITDA
3.24
Margins
EBITDA margin
-32.3%
Gross margin
66.2%
Net margin
-41.3%
Operating margin
-37.9%
Efficiency
Return on assets
-14.6%
Return on equity
-16.5%
Return on invested capital
-76%
Return on capital employed
-14.7%
Return on sales
-37.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AXNX stock price

How has the Axonics stock price performed over time
Intraday
3.43%
1 week
21.36%
1 month
17.99%
1 year
-10.77%
YTD
4.59%
QTD
-6.44%

Financial performance

How have Axonics's revenue and profit performed over time
Revenue
$194.34M
Gross profit
$128.56M
Operating income
-$73.73M
Net income
-$80.23M
Gross margin
66.2%
Net margin
-41.3%
AXNX's gross profit has surged by 81% year-on-year and by 11% since the previous quarter
The revenue has surged by 62% year-on-year and by 8% since the previous quarter
The net income has contracted by 28% YoY
The operating margin is up by 25% year-on-year and by 4.8% since the previous quarter

Growth

What is Axonics's growth rate over time

Valuation

What is Axonics stock price valuation
P/E
N/A
P/B
5.93
P/S
13.6
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
13.14
AXNX's EPS is down by 10% year-on-year but it is up by 3.2% since the previous quarter
AXNX's equity is up by 40% year-on-year but it is down by 3.9% since the previous quarter
The P/B is 2.2% above the last 4 quarters average of 5.8
The revenue has surged by 62% year-on-year and by 8% since the previous quarter
The price to sales (P/S) is 15% lower than the last 4 quarters average of 16.0

Efficiency

How efficient is Axonics business performance
AXNX's ROS is up by 25% year-on-year and by 5% since the previous quarter
AXNX's ROIC is down by 24% QoQ and by 23% YoY
The ROE has increased by 21% YoY and by 7% from the previous quarter
AXNX's ROA is up by 14% YoY and by 3.3% from the previous quarter

Dividends

What is AXNX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AXNX.

Financial health

How did Axonics financials performed over time
AXNX's quick ratio is up by 49% year-on-year
The total liabilities has declined by 46% year-on-year and by 5% since the previous quarter
The company's debt is 98% lower than its equity
AXNX's debt to equity has dropped by 92% year-on-year
The company's debt has shrunk by 88% YoY and by 3.2% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.